JPRN-C000000134已完成2 期
Phase II study of topotecan and cisplatin for elderly small-cell lung cancer - Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
Okayama Lung Cancer Study Group0 个研究点目标入组 55 人开始时间: 2005年9月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
This regimen produced a favorable survival outcome (median: 22.2 months), despite moderate-to-severe toxicity profiles.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 76years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Active concomitant malignancy Active interstitial pneumonia Massive effusions Unstable angina, recent myocardial infarction Uncontrolled diabetes Symptomatic brain metastasis Severe active infection Other severe complications Inappropriate condition for this study judged by physicians.
研究者
相似试验
已完成
2 期
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical CancerCervical CancerNCT00548418Washington University School of Medicine27
已完成
2 期
Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancerJPRN-C000000130Okayama Lung Cancer Study Group30
已完成
2 期
Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb TrialEpithelial Ovarian CancerNCT01630018Chong Kun Dang Pharmaceutical141
已完成
2 期
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung CancerCarcinoma, Small CellNCT00305942SCRI Development Innovations, LLC61
已完成
2 期
a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4Sarcoma, Soft TissueNCT00130858Cooperative Weichteilsarkom Study Group90